Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents
Kaushal Parikh¹, Shundong Cang², Arunabh Sekhi¹ and Delong Liu³*

Abstract
Dysregulation of the nucleo-cytoplasmic transport of proteins plays an important role in carcinogenesis. The nuclear export of proteins depends on the activity of transport proteins, exportins. Exportins belong to the karyopherin β superfamily. Exportin-1 (XPO1), also known as chromosomal region maintenance 1 (CRM1), mediates transport of around 220 proteins. In this review, we summarized the development of a new class of antitumor drugs, collectively known as selective inhibitors of nuclear export (SINE). KPT-330 (selinexor) as an oral agent is showing activities in early clinical trials in both solid tumors and hematological malignancies.

Keywords: SINE, KPT-330, Selinexor, Nuclear export

Introduction
The nucleo-cytoplasmic transport of proteins plays an important role in maintaining normal cellular functions. The nuclear export of proteins depends on the activity of transport proteins, exportins. Exportin-1 (XPO1), also known as chromosomal region maintenance 1 (CRM1), mediates transport of around 220 proteins [1-4]. XPO1 is the sole nuclear exporter of several tumor suppressor (TSP), growth regulatory (GRP) proteins. These include p53, p21, p73, Rb1, apc, bcr-abl, FOXO and STAT3. Under physiological conditions, the export of these proteins prevents them from overacting in the absence of DNA injury or other oncogenic activities [5,6]. In cancerous cells, however, this export of proteins inhibits their tumor suppressor activity and promotes tumorogenesis [6,7]. Many hematologic and solid tumor malignancies have elevated XPO1 levels [8-12]. Therefore, inhibiting XPO1 can be a potential treatment option. In this review, we will discuss a new class of potential antitumor drugs, collectively known as selective inhibitors of nuclear export (SINE). These agents can block the export of TSPs and GRPs, thus maintaining their intranuclear concentration and exert anti-cancer activity.

Nucleo-cytoplasmic transport and its inhibition by SINE compounds
XPO1 binds to the cargo proteins through a leucine rich nuclear export signal (NES) and transports the proteins through a membrane pore complex via a Ran-GTP gradient [13-15] (Figure 1). Several small molecule inhibitors of XPO1 are being studied. These include Leptomycin B (LMB), ratjadone, goniothalamin, N-azolylacrylates, anguimycin, and CBS9106 [16-21]. They bind covalently to the cysteine residue (Cys528) in the NES binding groove of XPO1 [18]. This binding irreversibly inactivates XPO1, leading to intranuclear accumulation of TSPs and GRPs. Of these, leptomycin B (LMB) has been studied most extensively in various cancer cell lines and murine xenograft tumor models. A phase 1 study of an XPO1 inhibitor showed only modest efficacy and severe dose limiting toxicity (e.g. malaise, anorexia, vomiting and nausea) [22]. The clinical trial was therefore discontinued. KOS-2462, a semisynthetic LMB derivative showed activity in mouse xenograft models without inducing significant toxicity [16]. CBS9106 is another small molecule oral reversible inhibitor of XPO1. It induced growth inhibition in several cancer cell lines [17]. Neither KOS-2462, nor CBS9106 have entered clinical trials.

Subsequently, several novel inhibitors of XPO1, collectively known as SINE compounds, have been developed. These compounds include KPT-330 (selinexor), KPT-335 (verdinexor), KPT-185, KPT-276, and KPT-251. Of these,
KPT-185 is the most studied compound in vitro with most potency. However, its use in vivo is limited by poor pharmacokinetics [23-25]. KPT-330 is nearly as potent as KPT-185 and has acceptable oral bioavailability. KPT-251 and KPT-176 are not as potent as KPT-185 but are bioavailable orally [23-25]. These agents are currently undergoing clinical trials for several solid and hematologic malignancies including breast, colon, pancreas, renal, multiple myeloma (MM), mantle cell leukemia (MCL), chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML).

SINE in pancreatic cancer
KPT-127, KPT-185, KPT-205, and KPT-227 were studied in pancreatic cancer cell lines [26]. Prostate apoptosis response-4 (PAR-4) is a proapoptotic protein in the nuclear and cytoplasmic compartments. PAR-4 translocates to the nucleus via XPO1 in external stress conditions to cause apoptosis [27]. PAR-4 is downregulated in pancreatic cancers. Downregulation of PAR-4 directly correlates to worsening outcomes in pancreatic cancer [28]. KPT-185 was shown to increase intranuclear PAR-4 without interfering with its import from the cytoplasm. It also induced PAR-4 phosphorylation, thus activating it and leading to apoptosis. Active SINEs had a median inhibitory concentration (IC₅₀) of 150 nmol/L and inhibited pancreatic cancer cell lines while sparing normal human pancreatic ductal epithelial cells. The in vivo effects were noted using KPT-330 (selinexor) in subcutaneous and orthotopic pancreatic cancer models in mice. Oral administration of KPT-330 led to significant tumor growth inhibition when compared with control or gemcitabine treatment [26]. KPT-330 treated mice had drastic reductions in tumor size as compared with controls. Thus, pre-clinical studies of CRM1 inhibition using SINE compounds revealed an attractive novel treatment of pancreatic cancer.

SINE in triple-negative breast cancer (TNBC) (ER⁻, PR⁻, Her2⁻)
Overexpression of survivin is associated with poor prognosis in breast cancer [29]. Survivin inhibits apoptosis by stabilizing X linked inhibitor of apoptosis (XIAP) in the cytoplasm [30]. Survivin expression is also directly affected by STAT3, a member of Janus-activated kinase (JAK)/STAT [31], which is increased in several malignancies including TNBC [32]. Cytoplasmic localization is required for survivin to inhibit apoptosis [30]. XPO1 mediates transport of survivin and STAT3 to the cytoplasm, and inhibits apoptosis [33,34]. Inhibition of XPO1 blocked STAT3 binding to survivin promoter and decreased survivin expression. In the meanwhile, it was shown that survivin was cleaved by caspase-3, therefore leading to overall decrease of survivin level [4].
In this early trial, KPT-330 was administered orally for 8–10 doses in a 28-day cycles to 103 patients (59/44 M/F; median age 61 years) across 12 dose levels. Dose limiting toxicities (DLT) (fatigue, dehydration, nausea) were noted. Dosing at 65 mg/m² BW is ongoing since maximal tolerated dosage (MTD) was not reached yet at the time of the report. There were 87 evaluable patients (pts) for response. Among them, there were 3 PR in colorectal cancer (KRAS mutant), melanoma (BRAFwt) and ovarian adenocarcinoma pts. Stable disease (SD) was seen in 39 pts, with 12 pts lasting over 6 months. All 5 evaluable pts with hormone and chemotherapy refractory prostate cancer (HRPC) achieved SD; Nine of 13 evaluable pts with squamous head and neck cancer had SD diseases. Further evaluations are ongoing.

**SINE in non-small cell lung cancer (NSCLC)**

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) are main treatment for patients with advanced NSCLC with EGFR exon 19 deletion or exon 21 substitution [36,37]. EGFR overexpression and p53 mutations are associated with poor outcomes in NSCLC [38,39]. As mentioned earlier, nuclear export of p53 is mediated by XPO1 [40]. Sun et al. studied the antitumor activity of KPT-330 against NSCLC in vitro and in vivo, and concluded that the antitumor activity of KPT-330 against NSCLC was independent of p53 mutational status [41]. The antitumor activity of KPT-330 against NSCLC was likely related to p73. p73 shares structural and functional similarities with p53 and cooperates with p53 to induce apoptosis [42]. In cells with mutant p53, p73 is shown to cause apoptosis via activation of p53-inducible genes [42]. KPT-330 caused dose-dependent growth inhibition of NSCLC with correlating decrease in XPO1 levels [41]. Moreover, KPT-330 can inhibit NSCLC cell growth even in EGFR-TKI resistant cancer cells. Combination of KPT-330 and cisplatin displayed synergistic

**SINE in renal cell carcinoma (RCC)**

Despite several approved drugs for metastatic RCC, the progression free survival remains only 1 to 2 years [44]. KPT-185 was studied in vitro in RCC cell lines [45]. XPO1 is overexpressed in high grade RCC. KPT-185 and its oral equivalent KPT-251 decreased XPO1 levels. They also compared SINE with sorafenib and found greater inhibition of tumor growth with KPT-251 at a higher dose of 75 mg/kg in mouse xenografts (p = 0.07) without any adverse effects. KPT-185 increased nuclear localization of p53 and its downstream protein p21 to cause cell cycle arrest. Also, cytosol p21 reduction leads to apoptosis. KPT-251 showed increased p53 and p21 nuclear levels in vivo. Sorafenib, on the other hand, decreased nuclear and cytoplasmic p21, thereby causing apoptosis [46]. These findings warrant further clinical studies using SINE as a treatment choice in RCC.

**SINE in melanoma**

BRAF kinase activation is present in about 50% of melanomas [47-52]. Treatment with BRAF and MEK inhibitors has been very successful, but the eventual development of resistance to these kinase inhibitors calls for more agents [51,53-60]. XPO1 expression is found to be increased in metastatic melanoma more than primary melanoma or nevi [61]. Hence, SINE can be a potential treatment for metastatic melanoma. Salas Fragomeni et al. conducted in vitro and in vivo studies in metastatic melanoma using SINE and BRAF inhibitors [62]. They concluded that BRAF inhibition by PLX-432 led to inhibition of cell proliferation in BRAF-mutant cell lines, but BRAF wild-type (WT) melanoma cell lines were relatively resistant [53,54]. However, SINEs inhibited cell proliferation and caused cytotoxicity across all cell lines, regardless of BRAF status. They also showed synergistic activity between SINE and PLX-432 in BRAF mutant melanoma. Furthermore, SINE and MEK inhibitors were also able to synergize with the three-way treatment (SINE/MEK/BRAF), achieving an even lower IC₅₀. SINE also caused G1/S phase cell cycle arrest, another effect synergized with concomitant BRAF inhibition in BRAF mutant cell lines. SINE also increased nuclear p53, retinoblastoma (Rb). An increase in ERK phosphorylation in the nucleus was also noticed. ERK phosphorylation has been linked to increased cellular proliferation and development of chemoresistance [61,63,64]. However, this SINE- induced ERK phosphorylation was
SINE in acute leukemia

SINE compounds have been studied as a novel anticancer strategy in multiple preclinical trials of hematologic malignancies. Higher levels of XPO1 are associated with poor prognosis in acute leukemia [65]. Earlier preclinical work demonstrated that KPT-185 inhibited proliferation and induced G1 phase cell cycle arrest in AML cell lines and primary AML blasts in vitro [25]. Nucleophosmin 1 (NPM1) is a nucleolar TSP that shuttles between the nucleolus and cytoplasm via the XPO1-RanGTP pathway and regulates p53 dependent cell death [66]. NPM1 mutations in AML cells were seen in 25% to 35% cases [67]. These mutations cause increased XPO1 binding and localization of NPM1 in the cytoplasm [68]. SINEs block this export of mutant NPM1 and induce antileukemic effects in AML cell lines and primary AML blasts [65]. Nucleophosmin 1 (NPM1) is a nucleolar TSP that shuttles between the nucleolus and cytoplasm via the XPO1-RanGTP pathway and regulates p53 dependent cell death [66]. NPM1 mutations in AML cells were seen in 25% to 35% cases [67]. These mutations cause increased XPO1 binding and localization of NPM1 in the cytoplasm [68]. SINEs block this export of mutant NPM1 and induce antileukemic effects in AML cell lines and primary AML blasts. AML blasts with NPM1 mutations were very responsive to KPT-185 and had an IC_{50} of 100 nmol/L. However, wild type (WT) NPM1 in AML cells were also sensitive to SINEs, indicating that other TSPs like p53 also have a role in the antileukemic effects of SINE. Kojima et al. further established that p53 is a major determinant in SINE induced cytotoxicity in AML, independent of NPM1. Mutant p53 samples were less sensitive to KPT-185 [65]. XPO1 inhibition by SINE also resulted in blast differentiation, likely due to upregulation by p53 and CEBPA [69], a protein essential for myeloid granulocytic differentiation via activation of several necessary genes [70,71]. SINEs were also shown to downregulate FLT3 and cKIT tyrosine kinase proteins [25], FLT3 gene mutation may coexist with NPM1 mutations [72]. SINE downregulated FLT3 and NPM1. Thus, SINEs can potentially target 2 critical pathways. cKIT mutations or overexpression also confer a worse prognosis in AML [73,74]. Kojima et al. demonstrated synergistic activity using the combination of SINE with MDM2 inhibitor Nutlin-3a. MDM2, frequently overexpressed in AML, is a p53-specific ligase, promoting p53 degradation [75]. Nutlin-3a is a selective MDM2 inhibitor, shown to increase nuclear and cytoplasmic p53 and induces p53 mediated apoptosis [75]. The addition of SINE to Nutlin-3a led to higher p53 nuclear level than by using either agent alone in vitro [65]. This combination strategy can be potentially effective not only in AML but in several other malignancies. Furthermore, SINEs are not shown to induce apoptosis in normal hematopoietic cells [23,65,76].

T cell-acute lymphoblastic leukemia (T-ALL) is fatal in about 50-70% of adult patients [77-79]. SINE has shown striking activity in preclinical study for treatment of T-ALL. KPT-185 and KPT-330 showed rapid apoptosis induction in T-ALL cell lines in vitro with acceptable IC_{50} [76]. In vivo treatment showed minimal gastrointestinal adverse effects.

Philadelphia chromosome positive ALL remains a challenge even with availability of multiple tyrosine kinase inhibitors [80,81]. Walker et al. demonstrated successful use of KPT-185 in vitro and KPT-330 in vivo in Philadelphia chromosome positive ALL (Ph + ALL) and chronic myeloid leukemia blast crisis (CML-BC). Combination with imatinib led to synergistic effects [82]. SINE treatment was associated with significant reduction in BCR-ABL + cells in mice, likely by reactivation of the tumor suppressor proteins PP2A, p53, p21 and FOXO3a [82].

The preliminary results of an ongoing phase I trial using KPT-330 in relapsed/refractory AML were presented Yee et al. recently. They showed that KPT-330 treatment given to heavily pretreated, refractory/refractory AML patients had no DLT. Out of the 32 evaluable patients, 4 (12%) showed complete response (CR) with hematological recovery, 1 (3%) showed marrow CR (mCR), mCR without hematological recovery was seen in 1 (3%) patient. Partial response (PR) was seen in 2 patients (6%). Eleven patients (34%) showed progression while 12 (37%) experienced stable disease after 30 days [83].

SINE in chronic leukemia

Even though more options are available now for chronic lymphocytic leukemia (CLL) therapy, p53 positive CLL still has poor prognosis [84-91]. Preclinical study by Lapalombella et al. using KPT-185 in vitro and KPT-251 in vivo showed promising results in chronic lymphocytic leukemia (CLL) cells [24]. KPT-185 induced nuclear retention of IκB. IκB is an endogenous inhibitor of the inflammatory antiapoptotic transcription factor NFkB, which is involved in the upregulation of MCL1, the most significant antiapoptotic protein associated with CLL [92,93]. KPT-185 induced MCL1 depletion, likely due to inactivation of NFκB by nuclear retention of IκB. Murine xenografts treated with KPT-251 showed significant improvement in survival when compared with fludarabine [24]. In a 37 year old patient with CML-AP resistant to multiple treatment options (TKIs, interferon, omacetaxine and azacitidine), a trial of selinexor (KPT-330) on a compassionate use protocol showed significant reduction in bone pain, spleen size, white blood cell count, and lactate dehydrogenase (LDH) level. Peripheral blood smears showed a dramatic reduction in immature myeloid blasts [82].

SINE in multiple myeloma (MM)

SINE was shown to induce cytotoxicity and inhibits osteoclastogenesis in multiple myeloma in vitro and in vivo [12]. High CRM1 expression was found to be associated with lytic bone disease (P = 0.008) and shorter...
survival (P = 0.024). CRM1 levels are higher in bortezomib resistant MM cells. SINEs caused nuclear accumulation of multiple TSPs including p53, FOXO3a, IkB, p21 and PP2A. SINE also caused anti-MM effects in the bone marrow microenvironment by activating caspase cascade and causing PARP cleavage, and showed a synergistic effect when combined with bortezomib, without affecting bone marrow stromal cells. Another study, however, observed no synergy with KPT-276 in combination with dexamethasone, bortezomib, or melphalan [94]. Osteoclastogenesis is controlled by NFKB activation through cytokine RANKL and NFAT1c. Both KTP-185 and KPT-330 blocked RANKL mediated activation of NFKB in osteoclast (OC) precursor cells, and also blocked NFKAT1c, which is also essential for osteoclast function [12,94]. Surprisingly, SINE reduced the expression of oncogene c-myc, despite the fact that CRM1 does not mediate c-myc export [95]. C-myc activation is associated with poor prognosis and shorter survival in monoclonal gammopathy of undetermined significance (MGUS) and MM [96]. A study done in 2012 indicated that p53 activation is responsible for inhibiting CRM1 and c-myc genes [97]. BRD4, another gene downregulated by SINE, regulates DNA replication, promotes c-myc transcription and is associated with MM disease progression [98,99]. BRD4 knockdown causes cell cycle arrest and subsequent apoptosis [98]. JQ1, a small molecule inhibitor of BRD4 gene causes decreased transcription of c-myc, an effect that was synergistic with KPT-276 [98]. This result can be utilized for further cytotoxic treatment of tumor cells in MM. Lastly, 2 week in vivo treatment with KPT-276 had a comparable effect on M-spike reduction with melphalan and bortezomib, the two potent anti-MM drugs [94].

**SINE in lymphoma**

Novel agents and regimens for lymphoma are moving rapidly from bench to bedside [89,100-104]. KPT drugs have been studied preclinically for the treatment of resistant mantle cell lymphoma (MCL). Yoshimura et al. conducted an in vitro study of KPT-185 in MCL and showed that SINE increases MCL cell apoptosis primarily by increasing nuclear p53 levels [105]. They verified that KPT-185 downregulated c-myc and NFKB, thus targeting multiple pathways of apoptosis. Zhang et al. studied the in vivo effects of KPT-276 in mice and showed marked activity with minimal weight loss, gastrointestinal side effects, or myelosuppression [106]. London et al. studied SINEs in vivo in a phase I clinical trial in spontaneous canine NHL, osteosarcoma or mast cell tumor. They used KPT-335 at a dose of 1 mg/kg to 1.75 mg/kg two times a week and showed significant response without development of serious side effects [107]. Gutierrez et al. presented the findings of their phase I study with KPT-330 in 32 pretreated refractory lymphoma patients. The optimal dosing of KPT-330 is at least 45 mg/m2 and durable activity of KPT-330 was observed in those NHL patients [108]. These data further validated the activity of SINEs in human malignancies.

**Future directions**

More and more targeted small molecule inhibitors are entering clinical application quickly [53,84,85,109-113]. Selective inhibitors of nuclear export (SINE) show activity in a wide variety of cancers, both hematologic and solid tumors [114,115]. Currently, they are being studied in early phase clinical trials (Table 1). Their low toxicity profile and synergistic effects in combination with other antineoplastic agents support further development in

Table 1  Selinexor (KPT-330) in clinical trials

| Diseases                                      | Trial       | Recruiting status | NCT number             |
|----------------------------------------------|-------------|-------------------|------------------------|
| Relapsed ALL and AML                         | Phase I     | Recruiting        | NCT02091245            |
| Unresectable melanoma                        | Phase I     | Not yet Recruiting| NCT02120222            |
| Gynaecologic malignancies                    | Phase II    | Recruiting        | NCT02025985            |
| Advanced/metastatic solid tumors             | Phase I     | Recruiting        | NCT02078349            |
| Soft-tissue or bone sarcoma                  | Phase Ib    | Recruiting        | NCT01896505            |
| Advanced/metastatic solid tumors             | Phase I     | Recruiting        | NCT01607905            |
| Metastatic resistant prostate cancer          | Phase II    | Recruiting        | NCT02146833            |
| Advanced hematological malignancies          | Phase I     | Recruiting        | NCT01607892            |
| Recurrent glioblastoma                       | Phase II    | Recruiting        | NCT01986348            |
| Relapsed/refractory AML                       | Phase II    | Recruiting        | NCT02088541            |
| Refractory/refractory CLL                    | Phase II    | Recruiting        | NCT02138786            |
| Acute myeloid leukemia                       | Phase I     | Recruiting        | NCT02093403            |
| Locally advanced rectal cancer               | Phase I     | Not yet Recruiting| NCT02137356            |

Note: details of all NCT trials can be found on www.clinicaltrials.gov.
combination regimens against a wide range of malignancies. SINES represent a unique, novel class of targeted agents for various malignancies.

Competing interest
The authors have no relevant competing interest.

Authors’ contributions
DL and KP designed the study. All authors have contributed to data preparation, drafting and revising the manuscripts. All authors have read and approved the final manuscript.

Acknowledgment
Dr. Shundong Cang is a recipient of CAHON Scholar award (www.CAHON.org) and was partly funded by International Scholar Exchange Foundation.

Author details
1Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA. 2Department of Oncology, People’s Hospital of Henan Province, Zhengzhou, China. 3Henan Tumor Hospital, Zhengzhou University, Zhengzhou, China.

Received: 25 August 2014 Accepted: 9 October 2014

References
1. Fukuta M, Arano S, Nakamura T, Adachi M, Yoshida M, Yangaida M, Niheda E: CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 1997, 390:308–311.
2. Xu D, Grishin NV, Chook YM: NESdb: a database of NES-containing CRM1 cargoes. Mol Biol Cell 2012, 23:3673–3676.
3. Nguyen KT, Holloway MP, Altura RA: The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol 2012, 21:137–151.
4. Cheng Y, Holloway MP, Nguyen K, McCauley D, Landersen Y, Kaufmann MG, Shacham S, Altura RA: CRM1 inhibition regresses STAS3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer. Mol Cancer Ther 2014, 13:675–680.
5. Kutay U, Hetzer MW: Reorganization of the nuclear envelope during open mitosis. Curr Opin Cell Biol 2008, 20:669–677.
6. Turner JG, Sullivan DM: CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem 2008, 15:2648–2655.
7. Turner JG, Dawson J, Sullivan DM: Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012, 83:1021–1032.
8. Noske A, Weichert W, Niesporek S, Röske A, Buckendahl AC, Koch I, Sehouli J, Dietel M, Denkt C: Expression of the nuclear export protein chromosomal region maintenance/exportin 1 (XPO1) is a prognostic factor in human ovarian cancer. Cancer 2008, 112:733–1743.
9. Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C: Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 2009, 65:153–159, discussion 159–160.
10. Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Chen P, Sun YJ, Tan LQ, Zheng SE: The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep 2010, 22:299–235.
11. Huang WY, Yue L, Qiu WS, Wang LW, Zhou HX, Sun YJ: Prognostic value of CRM1 in pancreatic cancer. Clin Invest Med 2009, 32:e2135.
12. Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, Tannenbaum D, Mohammad RM: Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology 2013, 144:467–456.
13. Sells SF, Han SS, Muthukumar S, Madiwar N, Johnstone R, Boghaert E, Mills J, Liu G, Nair P, Menogin S, Collini P, Mattson MP, Sukhatme VP, Zimmer SG, Wood DP, McRoberts JW, Shi Y, Rangnekar VM: Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol Cell Biol 1997, 17:3823–3832.
14. Ahmed MM, Sheldon D, Fruitwala MA, Venkatasubbarao K, Lee EY, Gupta S, Wood C, Muthukumar S, Strodel WE: Downregulation of Par-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation. Int J Cancer 2008, 122:623–630.
15. Tanaka K, Yamamoto S, Ono G, Nohara T, Iwamoto M, Tanigawa N: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000, 6:127–134.
16. Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuura S, Zou H, Armstrong R, Matsuura S, Salvesen GS, Reed JC, Altieri DC: An IAP–IAP complex inhibits apoptosis. J Biol Chem 2004, 279:30807–3090.
17. Furjan M, Mukhi N, Lee B, Liu D: Dysregulation of JAK–STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomarker Res 2013, 1:5.
18. Bromberg J, Darley JE: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19:2486–2473.
19. Rodríguez JA, Span SW, Ferreira CG, Kruyt FA, Giaccone G: CRM1-mediated nuclear export determines the cytoplasmic localization of the antitumor protein Survivin. Exp Cell Res 2002, 275:44–53.
20. Stauber RH, Rabenhorst U, Reik A, Engels K, Beer C, Knauer SK: Nucleocytoplasmatic shuttling and the biological activity of mouse survivin are regulated by an active nuclear export signal. Traffic 2006, 7:1461–1472.
class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors. ASCO Meeting Abstracts 2014, 32:2537.

Xu C, Zhou Q, Wu Y-L. Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? – A literature-based meta-analysis. J Hematol Oncol 2012, 5:62.

Niu F-Y, Wu Y-L. Novel agents and strategies for overcoming EGFR TKIs resistance. Exp Hematol Oncol 2014, 3:2.

Sharma S, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169–181.

Stewart DJ. Tumor and host factors that may limit efficacy of non-small cell lung cancer therapy. Crit Rev Oncol Hematol 2010, 73:173–234.

Strommel MJ, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, Wahl GW. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 1999, 18:1660–1672.

Sun H, Hatton N, Chien W, Sun Q, Sudo M, GI EL, Wu Y-L. V600E mutation. J Hematol Oncol 2014, 7:291.

Akarson PO, Haque S, Gavanev S, Ghesseir RA, Ricarte-Filho JC, Dominguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA. Selumetinib-enhanced radioloidine uptake in advanced thyroid cancer. N Engl J Med 2013, 368:523–532.

Yannie PA, Shaw AT, Perezis JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulia V, Smith P, Crino L. Selumetinib plus docetaxel for KRAS-mutant advanced non-small cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013, 14:38–47.

Mark JS, Gong Y, Chitale D, Golis B, McLellan MD, Kasi Y, Ding L, Mardis ER, Wilson RK, Solit D, Levine R, Michel K, Thomas KR, Rusch VW, Ladanay M, Pao W. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 2006, 68:5324–5326.

Pathria G, Wagner C, Wagner SN. Inhibition of CRM1-mediated nuclear translocation: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways. J Invest Dermatol 2012, 132:2780–2790.

Salas Fragomeni RA, Chung HW, Landeysn Y, Senapedis W, Saint-Martin JR, Tsao H, Flaherty KT, Shacham S, Kaufmann M, Cusack JC. CRM1 and BRAF signal transduction identifies tumor regression in BRAF-mutant melanoma. Mol Cancer Ther 2013, 12:1171–1179.

Cagnoli S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death–apoptosis, autophagy and senescence. FEMS J 2010, 272:7–21.

Mirmohammadiadeh A, Mota R, Guasta H, Hasan M, Nambaris S, Arjani B, Bojar H, Tannapfel A, Hengge UR. High phosphorylation in metastasis and chemotherapy resistance in melanoma cells from cisplatin-mediated apoptosis. J Invest Dermatol 2007, 127:2207–2215.

Kojima K, Kombial SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Kastelan H, Shacham S, Kaufmann M, Andreff M. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 2013, 121:4166–4174.

Saha M, Qiu L, Chang H. Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol 2013, 6:23.

Pawar R, Singh Ball OP, Malhotra BK, Lamba G. Recent advances and novel agents for FLT3 mutated AML. Stem Cell Invest 2014, 1:7.

Cheng K, Sportoletti P, Ito K, Klohesy JG, Teruya-Feldstein J, Kutok JL, Pandolfi PP. The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. Blood 2010, 115:3341–3345.

Yoon K, Smart RC. CEBPalpha is a DNA damage-inducible p53-regulated mediator of the G1 checkpoint in keratinocytes. Mol Cell Biol 2004, 24:10650–10660.

Keesan K, Santilli G, Corradini F, Perroti D, Calabretta B. Transcription activation function of CEBPalpha is required for induction of granulocytic differentiation. Blood 2003, 102:1267–1275.

Tenen DG, Hromas R, Licht JD. Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood 1997, 90:489–519.

Mrozek Z, Marcucci G, Paschka P, Whitman SB. CEBPalpha is a DNA damage-inducible p53-regulated mediator of the G1 checkpoint in keratinocytes. Mol Cell Biol 2004, 24:10650–10660.

Reha K, Kanakura Y, Tamaki T, Kuriya A, Kato H, Ishikawa J, Kitayama H, Kanayama Y, Watanabe K, Kitagawa M, Hida T, Kurokawa S, Ohashi Y. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 1991, 78:2962–2968.

Paschka P, Mrozek Z, Gurnett AS, Bhat KL, Chen H, Kittles RA, Vukosavicjevic T, Perrotti D, Vardiman JW, Caroll AJ, Kolitz JE, Larson RA, Bloomfield CD. Clinical relevance of mutations and gene expression changes in adult acute myeloid leukemia with normal karyotype: are we ready for a prognostically prioritized molecular classification? Blood 2007, 109:431–448.

Ida H, Tsumura H, Tsukada T, Maeda H, Iwajiri A, Ohno T, Isshiki H, Yanagawa A, Yonezawa N, Taniyama Y, Tsuchida D, Tani H. Expression and functional role of the proto-oncogene c-kit in acute myeloid leukemia: implications for drug development. Blood 1995, 86:4273–4279.

Ida H, Tsumura H, Tsukada T, Maeda H, Iwajiri A, Ohno T, Isshiki H, Yanagawa A, Yonezawa N, Taniyama Y, Tsuchida D, Tani H. Expression and functional role of the proto-oncogene c-kit in acute myeloid leukemia: implications for drug development. Blood 1995, 86:4273–4279.

Ida H, Tsumura H, Tsukada T, Maeda H, Iwajiri A, Ohno T, Isshiki H, Yanagawa A, Yonezawa N, Taniyama Y, Tsuchida D, Tani H. Expression and functional role of the proto-oncogene c-kit in acute myeloid leukemia: implications for drug development. Blood 1995, 86:4273–4279.

Ida H, Tsumura H, Tsukada T, Maeda H, Iwajiri A, Ohno T, Isshiki H, Yanagawa A, Yonezawa N, Taniyama Y, Tsuchida D, Tani H. Expression and functional role of the proto-oncogene c-kit in acute myeloid leukemia: implications for drug development. Blood 1995, 86:4273–4279.

Ida H, Tsumura H, Tsukada T, Maeda H, Iwajiri A, Ohno T, Isshiki H, Yanagawa A, Yonezawa N, Taniyama Y, Tsuchida D, Tani H. Expression and functional role of the proto-oncogene c-kit in acute myeloid leukemia: implications for drug development. Blood 1995, 86:4273–4279.

Ida H, Tsumura H, Tsukada T, Maeda H, Iwajiri A, Ohno T, Isshiki H, Yanagawa A, Yonezawa N, Taniyama Y, Tsuchida D, Tani H. Expression and functional role of the proto-oncogene c-kit in acute myeloid leukemia: implications for drug development. Blood 1995, 86:4273–4279.

Ida H, Tsumura H, Tsukada T, Maeda H, Iwajiri A, Ohno T, Isshiki H, Yanagawa A, Yonezawa N, Taniyama Y, Tsuchida D, Tani H. Expression and functional role of the proto-oncogene c-kit in acute myeloid leukemia: implications for drug development. Blood 1995, 86:4273–4279.
Targeting BTK with ibrutinib in relapsed or refractory chronic lymphocytic leukemia. J Hematol Oncol 2013, 6:40.

Fannsworth P, Ward D, Reddy V: Persistent complete molecular remission after nilotinib and graft-versus-leukemia effect in an acute lymphoblastic leukemia patient with cytogenetic relapse after allogeneic stem cell transplantation. Exp Hematol 2012, 40:129.

Nagafuku K, Miyamoto T, To T, Kamimura T, Taniguchi S, Okamura T, Chutsuka E, Yoshida T, Hisaichi M, Yoshimoto G, Fujisaki T, Abe Y, Takamatsu Y, Yokota S, Akashi K, Harada M: Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study). J Hematol Oncol 2013, 6:14.

Walker C, Oaks L, Santanaran R, Neviani P, Harb JG, Ferencak G, Ellis JJ, Landesman Y, Eisfeld AF, Gabrail NY, Smith CL, Caliguari MA, Holland P, Roy DC, Reid A, Miljkovic D, Goldman JM, Apperley JF, Apperley J, Garzon R, Marcuschi M, Shacham S, Kauffman MG, Perrotti D: Preclinical and clinical efficacy of XPO1 (CRM1) inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood 2013, 122:3034–3044.

Yue KWL, Savona M, Sorensen M, Brown P, Blum WG, DeAngelis DJ, Gutierrez M, Garzon R, Schuh AC, Gabrail NY, Wadleigh M, Lamacette JL, Shah BD, Beredjik JS, Wagner-Johnston ND, Flinn I, Rashal T, Kauffman M, Shacham S, Stone RM: A phase I dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 in patients with relapsed/refractory acute myeloid leukemia (AML). ASCO Meeting Abstracts 2014, 32:7032.

Akinleye A, Awaru P, Purpan M, Song Y, Liu D: Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol 2013, 6:88.

Akinleye A, Chen Y, Mukhi N, Song Y, Liu D, Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol 2013, 6:59.

Lu K, Wang X: Therapeutic advancement of chronic lymphocytic leukemia. J Hematol Oncol 2012, 5:35.

Wu M, Akinleye A, Zhu X: Novel agents for chronic lymphocytic leukemia. J Hematol Oncol 2013, 6:36.

Cang S, Mukhi N, Wang K, Liu D: Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol 2012, 6:54.

Wang K, Wei G, Liu D: CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 2012, 1:36.

Han E, Li KJ, Wang C-R, Li TF, Han S-Y: Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol 2013, 6:67.

Chen Y, Liu D: Chimeric antigen receptor (CAR)-directed adoptive immunotherapy: a new era in targeted cancer therapy. Stem Cell Invest 2014, 1:2.

Furman RR, Asagay M, McLain JF, Liu HC, Schattner E: Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000, 164:2200–2206.

Reed JC, Pellecchia M: Apoptosis-based therapies for hematologic malignancies. Blood 2005, 106:408–418.

Schmidt J, Braggio E, Kortuem KM, Egan JB, Zhu YX, Lin SY, Takeda J, Ozato K: The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase. J Biol Chem 2008, 283:5040–5046.

Fang X, Zhou X, Wang X: Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma. Biomarker Res 2013, 1:30.

Novero A, Ravella D, Chen Y, Dous G, Liu D, Ibrutinib for B cell malignancies. Exp Hematol Oncol 2014, 3:4.

Zhao X, Zhang W, Wang L, Zhao W-L: Genetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy. Biomarker Res 2013, 1:24.

Fischer K, Craver P, Busch R, Silgenber S, Bahlo J, Schweighofer CD, Bottcher S, Staib P, Kehl M, Eckart MJ, Kanz G, Goede V, Elter T, Buhler A, Winkler D, Kneba M, Döhner H, Eichhorst BF, Hallek M, Wendtner CM: Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011, 29:3559–3566.

Wierda WG, Padmananabhan S, Chan GW, Gupta IV, Lisby S, Osterbro A: Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 2011, 118:5126–5129.

Nagafuku K, Miyamoto T, Kama A, Ruiuso V, Dillop A, Quintás-Cardama A, McDonnell TJ, Neelapu SS, Kwak LW, Shacham S, Kauffman M, Tabe Y, Yokoi K, Kimura S, Andreff M, Kojima K: Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci 2014, 105:795–801.

Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, Zhang L, Ou L, Li C, Sun L, Ford RJ, Pham LV: Novel selective inhibitors of nuclear export (SINE) antagonists for therapy in mantle cell lymphoma. Exp Hematol 2013, 41:57–65.

Yoshimura M, Ishiha, A, Russo V, DiPilo A, Quintás-Cardama A, McDonnell TJ, Neelapu SS, Kwak LW, Shacham S, Kauffman M, Tabe Y, Yokoi K, Kimura S, Andreff M, Kojima K: Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci 2014, 105:795–801.

Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, Zhang L, Ou L, Li C, Sun L, Ford RJ, Pham LV: Novel selective inhibitors of nuclear export (SINE) antagonists for therapy in mantle cell lymphoma. Exp Hematol 2013, 41:57–65.